Pfizer and Valneva move Lyme vaccine submission to European Medicines Agency review

Pfizer is taking another step toward a potential Lyme disease vaccine in Europe, announcing that the European Medicines Agency (EMA) has validated the companies’ marketing authorization application for their candidate PF-07307405.

In a joint development with Valneva, Pfizer said the EMA validation effectively starts the agency’s review process for the submission. Marketing authorization applications are the formal requests a drugmaker submits to ask regulators to authorize a medicine’s sale, typically after earlier clinical development and manufacturing preparations.

The EMA’s validation is often treated as an administrative gateway. Once the application is considered complete enough to review, regulators can proceed to the core evaluation steps, including questions around the vaccine’s data package, proposed labeling, and manufacturing details, according to how the EU review workflow generally operates.

For Pfizer, Lyme disease is a continuing unmet need in public health, and a successful regulatory path could open a new franchise area beyond its existing portfolios. For Valneva, which co-developed the candidate with Pfizer, the EMA validation represents progress toward a decision that could determine whether the companies can commercialize the vaccine in the EU and potentially broader markets tied to EMA outcomes.

The companies did not provide in the announcement additional timing guidance or an estimated review length. They also did not detail which specific EMA committee or procedural milestone is next in the public communication accompanying the news.

Beyond the procedural advance, market participants typically watch regulatory review updates for indicates about whether regulators accept the data package without major follow-up questions. If the EMA proceeds without requests for additional information, it can be viewed as smoother than scenarios in which regulators ask for clarifications or supplementary analyses.

It also remains unclear from the announcement how the companies expect to handle manufacturing scale-up if authorization is granted, or whether they anticipate further clinical or regulatory work in parallel. Those items are often disclosed later, including around labeling negotiations, inspection planning, or post-submission Q&A.